Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 10/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.40 |
| ▸ | PRKCA | P17252 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829843 | 1.00 | PRKCQ (0.40) | PRKCQPRKCDPRKCAHDAC1JAK3 | |
| SCHEMBL1828261 | 0.89 | PRKCQ (0.43) | PRKCQPRKCDPRKCAJAK3PRKCB | |
| SCHEMBL10451288 | 0.81 | PPARG (0.36) | PRKCQPRKCDPRKCAHDAC1DPP4 | |
| SCHEMBL8512175 | 0.78 | HDAC1 (0.41) | HDAC1JAK3DPP4PIK3CDPARP1 | |
| SCHEMBL8512178 | 0.78 | HDAC1 (0.41) | HDAC1JAK3DPP4PIK3CDPARP1 | |
| SCHEMBL38666771 | 0.78 | JAK3 (0.41) | HDAC1JAK3DPP4PIK3CDMAP4K4 | |
| SCHEMBL17525864 | 0.73 | PRKCQ (0.63) | PRKCQPRKCDPRKCAHDAC1PRKCB | |
| SCHEMBL31087049 | 0.71 | HDAC1 (0.40) | HDAC1DPP4PARP1MAP4K4GPR119 | |
| SCHEMBL38665390 | 0.69 | HDAC1 (0.42) | HDAC1JAK3DPP4PARP1MAP4K4 | |
| SCHEMBL1922854 | 0.68 | PRKCQ (0.37) | PRKCQPRKCDPRKCAJAK3PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-8569337-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PRKCQ 51/4885PRKCD 144/4885PRKCA 34/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PRKCQ 51/4885PRKCD 144/4885PRKCA 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.